SKB BIO-B (06990): SKB445 New Drug Clinical Trial Application Approved by the National Medical Products Administration.

SKB BIO-B (06990) announced that the Board of Directors of the company is pleased to announce that on January 20, 2025, the company received a clinical trial notification letter from the National Medical Products Administration Drug Evaluation Center approving the company's application for clinical trials of the innovative drug SKB445. SKB445 is a novel ADC drug developed by the company using the OptiDC platform technology targeting specific biological markers. It has shown promising efficacy and safety in preclinical studies and is intended for the treatment of advanced solid tumors.